NPPA releases Revised MRP for 543 brands of Anti-Cancer Medicines; List to be updated on continual basis; New Prices Effective from November 9, 2026

1. At a Glance

• NPPA has published revised Maximum Retail Prices (MRPs) for 543 brands of anti-cancer medicines. The new prices take effect on 9 November 2026 [1].
• These prices follow from the Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs, announced on 17 October 2026 [1].
• TMR caps the margin earned between the manufacturer and the retailer. Normally, non-scheduled drugs have no price ceiling and are only watched under a 10% yearly limit on price increases [1][3].
• UPSC relevance: this sits where GS-II (health, access to medicines) meets GS-III (pricing regulation, the pharma industry). It is also a direct follow-up to the 2019 TMR pilot.

2. Why in the News

• 17 Oct 2026: NPPA announced TMR for 137 non-scheduled anti-cancer drugs "in public interest" to curb excessive trade margins. Manufacturers were told to submit revised price lists [1].
• Late Oct 2026: NPPA released revised MRPs for 543 brands, based on company submissions received up to 27 Oct 2026. The list will be updated continually as more submissions come in [1].
• Example: Bevacizumab 100 mg/4 ml injection (Abbott) falls from ₹21,767.70 to ₹5,930.13 [1]. That is a cut of about 72.8% (worked out from these two figures).
• Aug 2026: the Lok Sabha Standing Committee on Chemicals & Fertilizers (33rd Report) criticised the "inordinate delay" in building TMR permanently into DPCO 2013 [3].

3. Background & Evolution

• 1970: the Bureau of Industrial Costs and Prices (BICP) was set up. Along with the Tariff Commission and its predecessors, it advised on drug costing and pricing [3].
• 29 Aug 1997: NPPA was constituted by a Government Resolution published in Gazette No. 159. Drug price-fixing work moved from BICP to NPPA [3].
• 2008: the Department of Pharmaceuticals (DoP) was created under the Ministry of Chemicals & Fertilizers, and NPPA was placed under it [3].
• 7 Dec 2012: the National Pharmaceutical Pricing Policy (NPPP), 2012 was notified. Its principles are essentiality (based on NLEM), control of formulation prices only, and market-based pricing [3].
• DPCO 2013: moved drug pricing from cost-based to market-based [3].
• 2014: Para 19 was used to cap the MRPs of 106 non-scheduled formulations (22 for diabetes, 84 cardiovascular) [3].
• 13 Feb 2017: ceiling prices were fixed for coronary stents. 16 Aug 2017: ceiling prices were fixed for knee implants [3].
• 27 Feb 2019 (S.O. 1041(E)): the TMR pilot capped the trade margin at 30% on 42 non-scheduled anti-cancer drugs [3]. At the time, PIB put coverage at 72 formulations and 355 brands [2]. NPPA later reported that 526 brands fell by about 50% on average, saving patients about ₹984 crore a year [3].
• 1 Apr 2020: all medical devices were brought under DPCO 2013 (NPPA S.O. 1232(E)) [3].
• June–July 2021: TMR was applied to 6 COVID-related devices: oxygen concentrators, pulse oximeters, BP monitors, nebulisers, digital thermometers and glucometers. Margins were capped at 70% of Price to Distributor [3].
• Oct 2026: TMR was extended to 137 anti-cancer drugs, and revised MRPs were issued for 543 brands [1].

4. Core Static Facts

Item	Fact
Regulator	NPPA, an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [1][3]
Constituted	Resolution dated 29.8.1997 (Gazette No. 159) [3]
Governing order	Drugs (Prices Control) Order, 2013, issued under Section 3 of the Essential Commodities Act, 1955 [3]
Policy	NPPP 2012, notified 7.12.2012 [3]
Scheduled drugs	NLEM medicines placed in Schedule-I of DPCO 2013. NPPA fixes their ceiling prices under Paras 4 & 6 [3]
NLEM 2022	388 medicines, about 900+ formulations. Issued by MoHFW on the recommendation of the Standing National Committee on Medicines (SNCM) [3]
Ceiling prices in force	933 formulations (as of 23.10.2025) [3]
Annual revision	Para 16: ceiling prices are revised each year in line with the WPI, on or before 1 April [3]
New drug pricing	Para 5, with "new drug" defined in Para 2(1)(u). About 3,570 retail prices fixed up to 23.10.2025 [3]
Non-scheduled drugs	Manufacturers set the price. The MRP may rise by at most 10% in 12 months [3]
Actual non-scheduled price rise	Average of 5.6% a year (Apr 2020–Mar 2025), compared with WPI at 5.4% [3]
Extraordinary power	Para 19: prices can be fixed in public interest in extraordinary circumstances. TMR is carried out under this power [3]
Market split (FY25)	Scheduled drugs are about 18% of market value and non-scheduled about 82% [3]
State-level arm	Price Monitoring and Resource Units (PMRUs) in 32 States/UTs, working under the State Drugs Controllers [3]
2026 TMR	137 drugs and 543 brands, effective 9 Nov 2026 [1]
Drugs covered (examples)	Immunotherapy drugs (used in 20+ cancer types), Denosumab (breast and prostate cancer), Pegfilgrastim (prevents neutropenia), Bevacizumab (colon, ovarian and cervical cancers) [1]

5. Multi-Dimensional Analysis

Economic

• Non-scheduled drugs make up about 82% of market value, so ceiling prices alone leave most of the market uncontrolled. TMR targets margins in this segment without full price control [3].
• About 87% of the non-scheduled market has weighted average markups of up to 45%. Only about 4% has markups above 100% of the Price to Distributor. Excessive margins are therefore concentrated in a few segments, such as high-priced cancer drugs, which is why TMR is applied selectively [3].
• The 2019 pilot saved about ₹984 crore a year, which shows the scale of the potential fiscal benefit [3].

Social / Health equity

• Cancer treatment costs patients heavily out of pocket. Cuts of about 70% on biologics like Bevacizumab improve access for poor and middle-income patients [1].
• The drugs covered include supportive-care medicines such as Pegfilgrastim, not just cancer-killing drugs [1].

Legal / Regulatory

• TMR rests on Para 19, an extraordinary, time-limited power. DPCO 2013 has no permanent enabling provision for TMR [3].
• The Standing Committee recommended a permanent TMR framework within a defined timeframe. The Department said it has no set time frame [3].

Governance / Administrative

• Enforcement is staggered. Prices depend on manufacturers' submissions, and the list is "updated on a continual basis" [1].
• One known violation is selling old stock at pre-revised MRPs, which the Committee has flagged [3].
• Total overcharging demands against violators reached ₹10,013.30 crore [3], which shows how weak recovery has been.

Industry / Stakeholder

• MSME pharma associations have objected to TMR being applied to non-scheduled formulations. Stakeholders have also raised concerns about the "span and extent" of TMR [3].
• The Department warns that price cuts must not make products unviable to the point where life-saving drugs disappear from the market [3].

6. Recent Developments (last 12–18 months)

• 23 Oct 2025: ceiling prices were in force for 933 formulations. NPPA had fixed about 3,570 new-drug prices [3].
• Dec 2022 – Nov 2025: the Authority held 36 meetings. It fixed ceiling prices for 776 scheduled formulations and 1,425 new-drug retail prices [3].
• Aug 2026: the 33rd Report of the Standing Committee on Chemicals & Fertilizers (18th Lok Sabha) reviewed NPPA and pushed for permanent TMR [3].
• 17 Oct 2026: TMR was announced for 137 non-scheduled anti-cancer drugs [1].
• 27 Oct 2026: this was the cut-off date for the first batch of company price submissions [1].
• 9 Nov 2026: revised MRPs for 543 brands take effect [1].

7. Prelims Hooks

• NPPA is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. It is not under MoHFW [3].
• NPPA was constituted by a Government Resolution on 29 Aug 1997. It is not a statutory body [3].
• DPCO 2013 is issued under Section 3 of the Essential Commodities Act, 1955, not the Drugs & Cosmetics Act, 1940 [3].
• The NLEM is prepared by MoHFW through the SNCM. NLEM drugs form Schedule-I of DPCO 2013 [3].
• NLEM 2022 lists 388 medicines [3].
• Para 19 of DPCO 2013 allows price fixation in extraordinary circumstances in public interest. It is the legal basis for TMR [3].
• Para 16 of DPCO 2013 requires annual WPI-linked revision of ceiling prices [3].
• Non-scheduled drug MRPs may rise by at most 10% in 12 months [3].
• The first TMR pilot (27 Feb 2019) capped trade margins at 30% on 42 anti-cancer drugs [3].
• The 2026 TMR covers 137 drugs, with revised MRPs for 543 brands, effective 9 Nov 2026 [1].
• Pegfilgrastim prevents neutropenia in cancer patients [1].
• Denosumab is used for breast and prostate cancer patients [1].
• Bevacizumab 100 mg/4 ml falls from ₹21,767.70 to ₹5,930.13 [1].
• Coronary stents were first price-capped on 13 Feb 2017 under Para 19 [3].
• PMRUs operate in 32 States/UTs [3].

8. TMR Cuts the Middlemen's Share, Not the Factory Price

• What TMR touches and what it leaves alone
• A drug's price passes through three points: the price the company charges the distributor (PTD, Price to Distributor), the price the retailer pays (PTR, Price to Retailer), and the MRP the patient pays.
• TMR limits only the gap between the first point and the last. This gap is the trade margin, the money earned by distributors and chemists.

• The company's own selling price is not examined at all.

• NPPA has no legal power to check what a drug costs to make

• DPCO 2013 fixes prices only from market data, meaning the prices already charged in the market. It has 'no provision' for using cost-audit data, which shows the actual cost of making a drug [3].
• The NPPA representative told the Committee: 'I have no power to do cost audit' [3].

• So if a company sets a high price at the factory gate, TMR leaves it alone. TMR removes the extra markup added on top of that price, and nothing more.

• The Committee wants a way to look behind the price

• It says depending only on market data may fail to catch distortions caused by 'market monopolies' [3].
• It recommended that the Ministry consider bringing back cost-based pricing, through changes in the law, where markups are abnormally high [3].
• This matters for patented biologics, where one company may be the only seller.

9. Why the Price Falls on Paper Before It Falls at the Chemist

• Old stock is the most common way the new price is avoided
• When a price is cut, companies do not have to take back stock already in shops. They only have to make sure it is sold at the new, lower price [3].
• 'Ceiling price violation (including pre-manufactured stock)' was the biggest category of violation. Between April 2020 and March 2025 it had 366 cases and ₹177.14 crore detected, but only ₹21.89 crore was recovered [3].

• A revised MRP that starts on 9 November 2026 can still be beaten by boxes printed with the old MRP.

• Fines are demanded but rarely collected

• Of ₹10,013.30 crore in overcharging demands, ₹8,526.10 crore (about 85%) was still unpaid on 30.9.2025 [3].
• ₹5,944.16 crore is stuck in High Court or Supreme Court cases. 280 of those 345 cases have been pending for between 6 and more than 20 years [3].

• So a company gains more by overcharging and fighting the demand in court than by obeying.

• The dispute is about the margin itself

• Companies challenge demands on several grounds. One is how the 'trade margin' should be deducted from the overcharged amount [3].

• Until a permanent TMR rule defines this clearly, every new TMR order can lead to the same arguments.

• There are few people to enforce it

• 15 of NPPA's 48 sanctioned posts are vacant. It depends on legal consultants hired on contract [3].
• Few patients complain directly. The Pharma Jan Samadhan portal received only 66 of 1,316 complaints between 2022-23 and November 2025 [3].

10. NPPA Measures Margins Using Data From the Drug Trade Itself

• NPPA does not collect its own price data
• Para 9 of DPCO 2013 allows prices to be fixed using data from a private market-data company. NPPA uses Pharmarack Technologies [3].
• Pharmarack grew out of AIOCD Pharma. AIOCD is the All India Organisation of Chemists and Druggists [3]. Chemists are the very traders whose margins TMR cuts.

• This does not prove the data is biased. But the regulator depends on records from the trade it regulates.

• The data misses the places where cancer drugs are often sold

• Pharmarack covers about 70% of the Indian pharmaceutical market [3].
• It does not cover hospitals, dispensing doctors, Jan Aushadhi, trade generics or e-commerce [3].

• Cancer injections are often bought from hospital pharmacies. So the real margins on these sales cannot be seen.

• Large discounts show that big margins exist

• The Committee found hospitals and retailers giving discounts of 20% to 60% on MRP. This means large margins are built into the price [3].

• The Department itself admitted that 'something needs to be done' about huge margins in some parts of the distribution chain [3].

• The fix is already being worked on, slowly

• IPDMS 2.0 is NPPA's own online system for collecting price data from companies. 2,344 companies were registered on it by November 2025 [3].
• The Committee wants it built into an independent database, so NPPA no longer has to rely on outside data firms [3].

11. Why the Real Savings May Be Smaller Than the Headline

• The headline example is the best case, not the usual one
• In 2019, some MRPs fell by up to 90% [4]. But the average cut across 526 brands was about 50% [3].

• Bevacizumab's fall of about 73% is a single example. It does not tell you the typical cut in 2026.

• Savings are counted as if every patient paid the full MRP

• The ₹984 crore estimate compares the old MRP with the new MRP [3].
• Many patients did not pay the old MRP. Hospitals and chemists already gave discounts of 20% to 60% [3].
• AMRIT pharmacies, which cover oncology, already sell at up to 50% below MRP [3].

• For these patients, the real saving is the gap between the old discounted price and the new MRP. That gap is smaller.

• Who gains the most

• Patients who buy at full MRP from ordinary chemists gain the most. These are often patients far from big hospitals.
• So the policy helps people outside the AMRIT and Jan Aushadhi network the most.

12. The Best Case Against Capping Margins, and Where It Fails

• The objection, stated fairly
• MSME drug makers say TMR will hurt small firms, cost jobs and reduce the supply of medicines to remote areas [3].
• Their reasons: 'trade generics' (cheap generic medicines sold mainly through small distributors in rural and remote markets) make up about 8-9% of the market [3]. Distributors in this channel pay more for transport, for holding stock, for expired goods and for loans [3].
• In this model the trade, not the manufacturer, pays for marketing. So a high percentage margin is partly a real cost [3].
• The Department adds that strict price control discourages investment. The pharma sector grew 9.9% a year, slower than the 11.8% nominal GDP growth of the economy [3].

• WHO also warns that products may disappear from the market if markups do not cover suppliers' costs [5].

• What the objection gets right

• Medicines can become too cheap to make. NPPA itself allowed 50% price rises for drugs that had become unviable, in 2019, 2021 and 2024 [3].

• A flat, blanket margin cap on all non-scheduled drugs would hurt cheap rural generics the most.

• Why it does not apply well to cancer drugs

• The Department's own explanation says high percentage margins come from a low ex-factory price and low sales volume. A small cost looks large as a percentage of a cheap product [3].
• A ₹21,767 cancer injection is the opposite case [1]. Even a modest percentage margin on it earns many rupees.

• Only about 4% of the non-scheduled market has markups above 100% of PTD [3]. Choosing high-priced cancer drugs aims TMR at that small group, not at rural generics.

• So the honest conclusion is

• The MSME argument is a good reason to design TMR carefully. It is not a reason to drop TMR for expensive cancer drugs.

13. What a Permanent TMR Rule Should Fix

• DoP should write TMR into DPCO with a deadline
• Today TMR depends on Para 19, an emergency power used 'for a limited period' [3].
• The Department has worked on this for 5-6 years and says it has 'no set time frame' [3].

• The Committee asked for a permanent TMR framework 'within a clearly defined timeframe' [3].

• Use a margin that gets smaller as the price gets bigger

• WHO's 2020 pricing guideline suggests regressive markups. This means the allowed percentage margin falls as the drug's price rises [5].
• This answers both sides. Cheap rural generics keep a higher percentage to cover real costs. Costly cancer drugs get a lower percentage, so traders cannot earn huge sums in rupees.

• WHO also asks countries to publish the markup method and review it regularly [5].

• Give NPPA a limited power to check costs

• The Committee recommended cost-based pricing, through changes in the law, where markups are abnormally high [3].

• Make recovery faster than court cases

• The Committee wants three things [3]:

  • a time-bound, fast-track way to settle disputes outside court
  • a dedicated legal cell inside NPPA
  • clear rules on disputed points, such as how the trade margin is deducted from the overcharged amount

• Staff and data

• Fill the 15 vacant posts and approve the proposed 59 new posts in NPPA [3].

• Bring hospital and e-commerce sales into the price data [3].

• Let patients have a say

• Over three years, draft prices for 'new drugs' got about 30 comments. 29 came from companies and 1 from an industry association. None came from patients or consumer groups [3].
• The Committee asked DoP and NPPA to draw the public into price-setting [3]. A permanent TMR rule should be consulted on in the same open way.

14. Anchors for Answers

• Data: About 82% of the drug market by value is non-scheduled, which ceiling prices do not reach. Only about 4% of it has markups above 100% of PTD [3]
• Data: ₹8,526.10 crore of ₹10,013.30 crore in overcharging demands (about 85%) is unrecovered. 280 of 345 court cases are 6 to 20+ years old [3]
• Data: 15 of NPPA's 48 sanctioned posts are vacant [3]
• Report/Committee: Lok Sabha Standing Committee on Chemicals & Fertilizers, 33rd Report (August 2026). It called the delay in a permanent TMR 'inordinate' and recommended considering cost-based pricing where markups are abnormal [3]
• Law/Case: Para 19 of DPCO 2013 (emergency public-interest power, the current basis of TMR). DPCO is issued under Section 3 of the Essential Commodities Act, 1955, and violations can be penalised under Section 7 of the same Act [3]
• Comparison: WHO Guideline on Country Pharmaceutical Pricing Policies (2020) suggests regressive markups, where the percentage falls as the price rises, along with a published method and regular review [5]
• Scheme: AMRIT pharmacies (255 outlets, covering oncology, up to 50% off MRP, about ₹8,691 crore saved) and PMBJP/Jan Aushadhi (about 80% cheaper than leading brands) work alongside TMR [3]

15. Mains Relevance

• GS-II: Issues relating to development and management of Health; government policies and interventions.
• GS-III: Indian economy (pricing and regulation of industry); effects of liberalisation on industrial policy (the shift from cost-based to market-based pricing).
• Possible question stems: 1. "Trade Margin Rationalisation offers a middle path between price control and free markets in pharmaceuticals." Examine this with reference to the recent capping of anti-cancer drug margins. 2. Using extraordinary powers under Para 19 of DPCO 2013 is not a substitute for a permanent pricing framework. Critically analyse. 3. How far has drug price regulation in India balanced affordability with industry viability and availability of medicines?

16. Related Topics to Study Next

• NLEM 2022 and Schedule-I of DPCO: these decide which drugs are scheduled and which are not.
• NPPP 2012: the policy that introduced market-based pricing.
• Essential Commodities Act, 1955: the parent statute of DPCO.
• Jan Aushadhi (PMBJP): a parallel route to affordable medicines through generics.
• Medical devices under DPCO (2020): TMR on stents, knee implants and COVID-era devices.
• CDSCO and the Drugs & Cosmetics Act, 1940: quality regulation, as distinct from price regulation.
• Biosimilars: Bevacizumab, Denosumab and Pegfilgrastim are biologics, so link to biosimilar policy and pricing.
• Out-of-pocket health expenditure and the cancer burden: the case for affordability.

17. NCERT Concepts to Revise

• Price ceiling (Economy): Scheduled drugs get government-fixed ceiling prices; TMR extends a similar cap to margins on non-scheduled drugs.
• Maximum Retail Price (Economy): The article is about NPPA revising MRPs, the highest price patients can be charged, for 543 brands.
• Price control (Economy): DPCO 2013 and TMR are forms of price regulation, balancing affordability against industry viability.
• Essential commodities (Economy): DPCO is issued under the Essential Commodities Act, 1955, the legal base for drug price control.
• Wholesale Price Index (Economy): Ceiling prices are revised every year in line with WPI, and non-scheduled price rises are compared to it.
• Standing committee (Polity): The Lok Sabha Standing Committee's 33rd Report criticised the delay in a permanent TMR framework.

18. Common Errors / Trap Areas

• Wrong ministry: NPPA is under the Ministry of Chemicals & Fertilizers (DoP), while the NLEM comes from MoHFW. Students often mix these up [3].
• 137 vs 543: 137 is the number of drugs under TMR, and 543 is the number of brands with revised MRPs [1].
• 2019 vs 2026: 2019 covered 42 drugs and 2026 covers 137 [1][3]. The 2019 brand count differs by source: 355 at launch [2] and 526 in a later NPPA report [3].
• Scheduled vs non-scheduled: TMR applies to non-scheduled drugs. Scheduled drugs already have ceiling prices [1][3].
• Statutory basis: DPCO comes from the Essential Commodities Act, not the Drugs & Cosmetics Act. NPPA was created by resolution, not by statute [3].